218 drugs, a batch of hospitals not for sale (with list)

Another batch of drug scrapping on December 8, Ningxia Hui Autonomous Region Public Resources Trading Service Center updated a message: after the expert review committee research decision, agreed to 100 enterprises on the drug scrapping bid (revoke the net) application, to cancel the above enterprise drug winning bid (hanging net) qualification.
public notice period is from 8 December to 15 December 2020 for a total of 5 working days.
Cypress Blue combed and found that a total of 218 drug waste labels: including hydrochloric acid kawasium injection, trinity capsules, libawelin particles, compound beneficial liver tablets, coughing syrup, hedgehog injection, injection of ampicillin sodium Shubatan sodium, nofluorosa star Capsules, cephalosporadine capsules, injection cyclophosphate adenosine, Budinide powder inhalation agent, injection of benzodiacylin sodium, bear deoxycholic acid tablets, naglina tablets, tuklutin sodium chloride injection, cytophospholine sodium glucose injection, injection of meloxirin sodium and many other varieties.
of the 218 drugs, 61 were low-cost drugs, 10 were basic infusion drugs, 13 were emergency (snatching) and 112 were not tendered for drugs, while 129 non-essential drugs were classified according to the source of the procurement.
do you bear the pain of scrapping the label? In fact, from a national perspective, the news of pharmaceutical companies actively scrapping the bid is not uncommon: Fujian, Zhejiang, Gansu, Sichuan and other provinces have appeared, the impact on enterprises can not be underestimated: the application for scrapping the mark means to exit the market, and more importantly, may be included in the deprecation list because of poor credit, the follow-up product access and market development impact.
For example, the State Health Insurance Administration issued the "Guidance on the establishment of a medical price and credit evaluation system" "Pharmaceutical prices and recruitment credit evaluation of the operating norms", intended to establish a list of pharmaceutical prices and recruitment of credit matters, and assess the pharmaceutical enterprises in the local tender procurement market, which from the national level to restrict and regulate the recruitment of pharmaceutical enterprises.
from this data, a total of 61 of the 218 drugs are low-cost drugs, which partly reflects the consideration of drug companies to scrap the bid - the winning bid is too low, that is, the industry called the "winning bid dead."
Previously, there have been officials said: many shortage of drugs because the price is too low "tender dead", "winning the bid dead" phenomenon, although the drug tender price is not a bad thing, the starting point is good, but sometimes the price pressure is low, even if the winning bid, in the long run, the production of more profit is not much, difficult to sustain.
People's Daily also reported that a survey of more than 100 physical enterprises in Suzhou and Wuxi in Jiangsu Province, Wuhan and Yichang in Hubei Province, Chengdu and Deyang provinces in Sichuan Province found that the "lowest bid" has become a problem of enterprise concentration.
experts said: In the pharmaceutical bidding season, a large number of enterprises withdraw the bid and cost increases at the same time the winning bid price is too low, corporate profits are significantly compressed closely related.
, the measurement of price by enterprises has indirectly led to the strategic abandonment of the market.
Because Ningxia's market is relatively small, in the bidding season joint price linkage of the comprehensive consideration, some pharmaceutical companies give up the price of the market, standing in the overall consideration of the maintenance price of the point of view, give up part of the market, had to make a loss of the car to protect the handsome initiative.
the use of auxiliary drug waste standard Cypress blue found that the waste of the varieties, there are some are focused on monitoring the rational use of drug species, or all over the auxiliary drug catalog of regular customers.
to some extent, although complementary drug varieties used to take up a lot of health insurance funds, drug use of large varieties, as the policy continues to tighten, auxiliary drugs and other market share is shrinking.
There are securities companies analysis that, in the context of further tightening of medical insurance charges, structural adjustment continues to deepen, the publication of the national version of the catalog and local implementation or will further squeeze the space for auxiliary drug use, including immunomodulants, neurotrophic agents, as well as some cardiovascular drugs in the local catalog into more.
China's official platform for rational drug use has also published data on the rational use of drugs in a hospital, confirming that the introduction of the national key monitoring drug catalog has far-reaching implications.
In the three years since the hospital, sales of neurology-assisted drugs have slowed, such as sales of sodium glycoside monosalic acid injections, which fell from $4.2989 million in 2017 to $2.5648 million in 2019.
For many pharmaceutical companies, with the auxiliary drug has become a strict control of the object, adjust the product layout has become a matter for enterprises to consider, which further led to the company's waste of some varieties of consideration, but in general, the current pharmaceutical companies, from the original low price at all costs, into now desperately adhere to the price bottom line.
how many pharmaceutical companies in the future how many product regulations will be due to drug prices and other factors to actively scrap the bid, this we do not know.
under the policies of consistent evaluation, local medical insurance catalog clearance, and price reduction, the industry reshuffle intensified, and enterprises needed to comb and streamline their product lines and actively transition to innovation.
same time, enterprises must also focus on the real clinically needed varieties - to a certain extent, only drugs with good therapeutic effects, few adverse reactions, affordable and reasonable advantages can occupy the longer market.
。